The combination of mebendazole and MEK inhibitor (trametinib) dramatically inhibited ERK1/2 phosphorylation, suppressed the ERK1/2‐mediated pathways, and decreased expression of BCL2 in NRASQ61K melanoma cell lines [331]. Here, BCL2 is linked to melanoma.